Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our lead products include PF582, a biosimilar candidate to Lucentis (ranibizumab) and PF708, a therapeutic equivalent to Forteo (teriparatide). Lucentis, marketed by F. Hoffmann-La Roche and Novartis AG, for the treatment of retinal diseases, achieved approximately $3.2 billion in 2016 global sales. Forteo, marketed by Eli Lilly and Company, for the treatment of high-risk fracture patients, achieved approximately $1.5 billion in 2016 global sales.
Our patented protein production platform, Pfenex Expression Technology, enables our ability to produce complex proteins relative to other systems. With advantages including quality, stability, solubility, and purity, Pfenex reduces production and development costs that enables the rapid delivery of protein products into clinical development and commercialization.
The information on this website, including any investor downloads, is not an offer to sell or solicitation of an offer to buy any interest in the company. Any offer of solicitation will be made only by means of a confidential private offering memorandum or registration statement relating to any such interest in the company and solely in those jurisdictions where permitted by law. We ask that you review our “Legal Notice” section of the website, which includes important information you should consider prior to accessing these investor downloads. Downloading these files constitutes your acceptance and understanding of our Legal Notice. The Legal Notice includes important information relating to, among other things, use of and reliance upon the content of this website, our use of forward looking information and other important disclaimers. Please contact us prior to downloading if you have any questions.